New Xtandi data bolster case for pre-chemo use
This article was originally published in Scrip
Astellas and Medivation reported a 10-month progression-free survival benefit for Xtandi (enzalutamide) versus Casodex (bicalutamide) in a Phase II clinical trial designed to satisfy requests for a head-to-head comparison of the androgen receptor inhibitors in metastatic castrate-resistant prostate cancer (mCRPC).
You may also be interested in...
As the CEO of Axovant, David Hung is back where he started with Medivation – working on a drug for Alzheimer's disease.
After two months of public, hostile back-and-forth, Sanofi agreed to confidentially discuss a potential acquisition of Medivation, putting the French pharma on equal footing with the biotech company's other suitors.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.